TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD DisclosureItem 7.01
Tonix Pharmaceuticals Holding Corp. (the “Company”) updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.01 hereto and incorporated herein by reference.
On December 12, 2017, the Company issued a press release announcing its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets). A copy of the press release is filed as Exhibit 99.02 hereto and incorporated herein by reference.
The information in this Current Report, including all exhibits, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing, and is not deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
| Item 9.01 | Financial Statements and Exhibits. |
______
* Furnished herewith.
Tonix Pharmaceuticals Holding Corp. ExhibitEX-99.01 2 s108407_ex99-01.htm EXHIBIT 99.01 Exhibit 99.01 © 2017 Tonix Pharmaceuticals Holding Corp. December 2017 Version P0089 12 – 12 – 17 (Doc 0303) Investor Presentation © 2017 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward – Looking Statements Certain statements in this presentation regarding strategic plans,…To view the full exhibit click here